Incyte

Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'
Investors Business Daily
Mon, 03/17/25 - 10:14 pm
Incyte
povorcitinib
clinical trials
hidradenitis suppurativa
Incyte posts phase 3 skin condition wins but details disappoint, sinking stock
Fierce Biotech
Mon, 03/17/25 - 11:05 am
Incyte
clinical trials
povorcitinib
Incyte exits immuno-oncology pact, leaving Agenus weighing options for assets
Fierce Biotech
Tue, 02/11/25 - 11:28 am
Incyte
immuno-oncology
Agenus
Incyte's JAK cream Opzelura picks up steam as company works to revive Jakafi XR dreams
Fierce Pharma
Mon, 02/10/25 - 10:27 pm
Incyte
Opzelura
Jakafi
JPM25: Incyte plans to turn 'a lot of cards' in 2025 as CEO eyes 2 types of deals
Fierce Pharma
Wed, 01/22/25 - 07:24 pm
JPMHC 2025
Pharma CEOs
Incyte
Hervé Hoppenot
Incyte scraps anemia program after drug fails to improve symptoms in rare blood cancer
Fierce Biotech
Sun, 12/15/24 - 10:46 pm
Incyte
myelofibrosis
anemia
zilurgisertib
Incyte sinks on setback for drugs acquired in $750M buyout
BioPharma Dive
Tue, 11/19/24 - 07:10 pm
Incyte
Escient Pharma
M&A
Incyte blocks US launch of Sun Pharma's alopecia drug
Pharmaphorum
Mon, 11/4/24 - 11:10 am
Incyte
Sun Pharma
Leqselvi
alopecia areata
With Jakafi's patent cliff looming, Incyte looks to 2025 launches to bulk up revenue by decade's end
Fierce Pharma
Wed, 10/30/24 - 11:42 am
Incyte
Jakafi
patent cliff
Niktimvo
graft vs host disease
Monjuvi
follicular lymphoma
Zynyz
squamous cell anal carcinoma
ESMO: Even after unique trial win, Incyte CEO views PD-1 drug Zynyz as pipeline aide
Fierce Pharma
Sun, 09/15/24 - 06:27 pm
Incyte
Zynyz
ESMO
Incyte and Syndax's immunotherapy for transplant complications receives FDA approval
Biopharma Reporter
Tue, 08/20/24 - 11:49 am
Incyte
Syndax
immunotherapy
Niktimvo
graft vs host disease
Armed with Phase III win, Incyte eyes label expansion for Monjuvi
Clinical Trials Arena
Fri, 08/16/24 - 11:19 am
Incyte
clinical trials
Monjuvi
relapsed or refractory follicular lymphoma
FDA approves Incyte's treatment for chronic graft-versus-host disease
Reuters
Wed, 08/14/24 - 10:37 pm
Incyte
FDA
graft vs host disease
Niktimvo
Incyte drops pair of PD-L1 drugs as part of 2nd pipeline clear-out this year
Fierce Biotech
Tue, 07/30/24 - 11:44 am
Incyte
anti-PD-L1
Incyte plots Delaware expansion as it looks to re-wed commercial, medical teams in its home state
Fierce Pharma
Tue, 05/21/24 - 06:56 pm
Incyte
Delaware
Opzelura
Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidates
BioSpace
Tue, 04/23/24 - 09:46 pm
Incyte
M&A
Escient Pharma
atopic dermatitis
Incyte, itching for a piece of Dupixent's market, hits goals in midphase skin disease trial
Fierce Biotech
Mon, 03/11/24 - 11:52 am
Incyte
clinical trials
prurigo nodularis
povorcitinib
Dupixent
Sanofi
Regeneron
Incyte vets, with phase 1 within reach, raise $102M for new biotech to create better PARP, PI3K drugs
Fierce Biotech
Wed, 01/24/24 - 10:35 am
Synnovation Therapeutics
Incyte
AstraZeneca
GSK
Novartis
Pfizer
funding
cancer
PARP inhibitors
Incyte reports positive data from Phase III vitiligo trial
Clinical Trials Arena
Thu, 10/12/23 - 05:27 pm
Incyte
Opzelura
vitiligo
clinical trials
Replimune and Incyte to study cancer combo therapy in CSCC patients
Clinical Trials Arena
Tue, 08/1/23 - 10:06 am
Replimmune
Incyte
clinical trials
RP1
CSCC
cutaneous squamous cell carcinoma

Pages